UroGen Pharma (URGN) director awarded 8,000 RSUs and 10,000 options
Rhea-AI Filing Summary
UroGen Pharma Ltd. director James A. Robinson Jr. reported equity awards that increase his potential ownership in the company. On June 22, 2026, he received 8,000 restricted stock units (RSUs), each representing one ordinary share upon vesting. He was also granted stock options on 10,000 ordinary shares with an exercise price of $34.99 per share and an expiration date of June 22, 2036. Both the RSUs and the option shares vest in equal quarterly installments over one year, contingent on his continued board service. After these grants, his reported holdings from these awards are 8,000 RSUs and 10,000 options, reflecting routine director compensation rather than open‑market trading.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Robinson James A. Jr.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right ot buy) | 10,000 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 8,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right ot buy) — 10,000 shares (Direct);
Restricted Stock Unit — 8,000 shares (Direct)
Footnotes (3)
- F1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
- F2. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- F3. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Key Figures
RSUs granted: 8,000 units
Options granted: 10,000 options
Option exercise price: $34.99 per share
+3 more
6 metrics
RSUs granted
8,000 units
Restricted stock units granted on June 22, 2026
Options granted
10,000 options
Stock options granted on June 22, 2026
Option exercise price
$34.99 per share
Exercise price for 10,000 stock options
Option expiration
June 22, 2036
Expiration date of the stock options
RSU underlying shares
8,000 ordinary shares
Each RSU converts into one ordinary share upon vesting
Option underlying shares
10,000 ordinary shares
Shares purchasable upon exercising the options
Key Terms
Restricted Stock Unit, Stock Option, Continuous Service, 2017 Equity Incentive Plan
4 terms
Restricted Stock Unit financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option financial
"The shares underlying the stock option will vest in equal quarterly installments"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Continuous Service financial
"subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan)"
2017 Equity Incentive Plan financial
"as defined in the 2017 Equity Incentive Plan through such vesting dates"
FAQ
What did UroGen Pharma (URGN) director James A. Robinson Jr. receive in this Form 4?
He received equity-based compensation: 8,000 restricted stock units and 10,000 stock options. These awards give him potential future ownership in UroGen Pharma, subject to vesting conditions and, for options, paying the stated exercise price.
How many restricted stock units were granted to the UroGen Pharma (URGN) director?
He was granted 8,000 restricted stock units. Each RSU represents a contingent right to receive one ordinary share of UroGen Pharma, delivered only as the units vest over time under the company’s equity plan.
What are the key terms of the stock options granted to the UroGen Pharma (URGN) director?
He received options on 10,000 ordinary shares at an exercise price of $34.99, expiring June 22, 2036. The options vest in equal quarterly installments over one year, conditioned on his continuous service as a director.
How do the RSUs for UroGen Pharma (URGN) vest for the director?
The 8,000 RSUs vest in equal quarterly installments over one year. Vesting depends on the director maintaining “Continuous Service” under UroGen Pharma’s 2017 Equity Incentive Plan through each scheduled vesting date.
Are these UroGen Pharma (URGN) insider transactions open-market buys or sales?
They are not open-market trades. The Form 4 shows compensation-related grants coded as “A,” meaning awards of RSUs and stock options from the company, rather than purchases or sales on the stock market.
What does each UroGen Pharma (URGN) RSU represent for the director?
Each restricted stock unit represents a contingent right to receive one ordinary share of UroGen Pharma. The director only receives the actual shares as the RSUs vest under the plan’s service-based conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
